Close

Transgenomic to advance pancreatic cancer research with NIH grant

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Transgenomic, a global biotechnology company, has won $100,000 small business technology transfer programme (STTR) Phase I grant from National Institutes of Health’s (NIH) National Center for pancreatic cancer research.

The project aims at developing sensitive diagnostic assay for the early detection of pancreatic ductal adenocarcinoma.

With a team at University of Nebraska Medical Center, Transgenomic will test the application of its proprietary ICE COLD-PCR technology to the sensitivity detection of key mutations in pancreatic cancer in pancreas, urine and blood.

Upon the successful outcome of the Phase I studies, a Phase II STTR application will be submitted to include more studies of ICE COLD-PCR detection of DNA mutations associated with early and late stage pancreatic cancer in humans.

Transgenomic chief executive officer Craig Tuttle said the ICE COLD-PCR technology is being able to deliver high-sensitivity genetic information to support the treatment of oncology patients, such as those suffering from pancreatic cancer.

“Both the financial support of the NIH and working with prominent cancer research groups, such as Dr. Hollingsworth and his team, will accelerate the development of our high-sensitivity cancer diagnostic assays,” Tuttle added.

Latest stories

Related stories

Rina-S Shows Promise in Advanced Ovarian Cancer

Genmab has reported encouraging findings from the Phase 2...

Revolutionizing Pharma Manufacturing with Biofermentation

Synthetic Chemistry and Integrated Biofermentation Transformational Pharmaceutical Manufacturing Combining biofermentation...

Thermo Fisher Launches Adolescent Alopecia Areata Registry

Thermo Fisher Scientific Inc., the global leader in serving...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back